BOLT Bolt Biotherapeutics, Inc.
Healthcare$5.13+3.64%ClosedMarket Cap: $9.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.47
P/S
1.46
EV/EBITDA
-0.70
DCF Value
$-97.01
FCF Yield
-279.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
96.9%
Operating Margin
-463.4%
Net Margin
-455.1%
ROE
-100.9%
ROA
-61.6%
ROIC
-69.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $26.0K | -680.8% | $-7.6M | $-7.2M | $— | — |
| Q4 null | $2.5M | 100.0% | $-5.6M | $-6.6M | $— | — |
| FY null | $7.7M | 80.6% | $-34.6M | $-33.4M | $— | — |
| Q3 null | $2.2M | 100.0% | $-7.7M | $-7.1M | $— | — |
| Q2 null | $1.8M | 100.0% | $-9.2M | $-8.6M | $— | — |
| Q1 null | $1.2M | 100.0% | $-12.1M | $-11.0M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-15.7M | $-15.9M | $— | — |
| FY null | $7.7M | 100.0% | $-73.0M | $-63.1M | $— | — |
| Q3 null | $1.1M | 100.0% | $-16.4M | $-15.2M | $— | — |
| Q2 null | $1.3M | 100.0% | $-22.6M | $-21.2M | $— | — |
| Q1 null | $5.3M | 91.3% | $-17.1M | $-10.8M | $— | — |
| Q4 2023 | $2.1M | -681.3% | $-19.8M | $-17.9M | $-0.47 | — |